FLUKE-RELIABILITY
16.9.2020 12:02:36 CEST | Business Wire | Press release
Prüftechnik, a division of Fluke Reliability, introduces the ShaftAlign Touch laser alignment system, a new digital solution that exceeds the capabilities of conventional tools and delivers greater speed and accuracy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200916005134/en/
The user-friendly system combines premium single-laser technology with Active Situational Intelligence to empower teams of varying experience levels to align most any asset with new levels of precision and speed. Prüftechnik Adaptive Alignment systems, such as the ShaftAlign Touch, automatically eliminate user errors and low-quality measurement points by adapting to the asset, the alignment situation, and the technician who is performing the job. Cloud-compatible software allows newer technicians to share measurements with more experienced colleagues or consultants — inside the plant or across the globe — to complete a job.
“ShaftAlign Touch is a significant improvement over conventional shaft alignment measurement equipment and basic laser systems in the market,” said Ankush Malhotra, vice president and general manager of Fluke Reliability. “With its intuitive computer-based, guided user interface, single-laser technology, and cloud-transfer capabilities, ShaftAlign Touch, sets a new benchmark for solving alignment issues at an unbeatable price/performance ratio.”
ShaftAlign Touch delivers:
- High performance and precise results — ShaftAlign Touch leverages single-laser technology to provide high-precision, high-performance alignment measurements.
- Quick setup and intuitive user interface — its swift setup and tablet-like, intuitive guided user interface make it more user-friendly than any of the conventional alignment measurement methods.
- Ability to share data via the cloud — technicians can leverage its integrated Wi-Fi cloud solution to easily transfer measurement data from the ShaftAlign Touch handheld device to the ARC 4.0 software.
ShaftAlign Touch is the latest addition to the family of Prüftechnik Adaptive Alignment laser systems. Adaptive Alignment is a combination of software and hardware that enables maintenance and reliability teams to adjust to most any horizontal, angular, or vertical alignment challenge. With Adaptive Alignment solutions, work is completed faster, results are more accurate, and team capabilities are better utilized compared to other market solutions.
For more information on the Prüftechnik ShaftAlign Touch, visit https://www.pruftechnik.com/en-US/Products-and-Services/Alignment-Systems-for-Rotating-Machinery/Shaft-Alignment/Shaft-Alignment-Systems/SHAFTALIGN-touch/ .
About Prüftechnik
Prüftechnik is a worldwide provider of maintenance technology with a comprehensive product, service, and training program tailored to the needs of maintenance experts in shaft alignment, vibration analysis, condition monitoring, and destruction-free testing. Many manufacturing companies worldwide trust its solutions for reliable and condition-based maintenance of rotating machines. For more information, visit https://www.pruftechnik.com .
About Fluke Reliability
Fluke Reliability offers reliability and maintenance teams the tools, software, and services they need to optimize asset performance. Home to three powerful iconic brands – Prüftechnik, eMaint, and Fluke Connect – Fluke Reliability serves more than 70,000 customers worldwide with a relentless dedication to quality, innovation, and service. Its products inform customers on the health of their assets, and its software and services drive better maintenance decisions – improving productivity, driving uptime, and reducing costs. For more information, visit https://www.accelix.com .
FLUKE is a registered trademark of Fluke Corporation. For more information, visit the Fluke website.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200916005134/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom